Alkermes plc.
corporate_fare Company Profile
Alkermes plc. (NASDAQ:ALKS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for ALKS at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Alkermes Reports FY2025 Revenue & Profit Decline, Projects FY2026 Net Loss Amid Strategic Investments
- Alkermes Reports Q4/FY 2025 Results, Projects FY 2026 GAAP Net Loss Amidst Strategic Investments
- Alkermes Completes Avadel Acquisition, Secures $1.525B Term Loans to Fund Strategic Expansion into Sleep Medicine
- Alkermes Highlights Strong 2025 Revenue, Alixorexton Breakthrough Therapy, and Strategic Avadel Acquisition
- Alkermes' Alixorexton Receives FDA Breakthrough Therapy Designation for Narcolepsy Type 1
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$1.48B
Net Income
$241.66M
Diluted EPS
$1.43
Op. Cash Flow
$520.75M
Free Cash Flow
$480.33M
Gross Profit
$1.28B
Operating Income
$253.96M
Cash & Equivalents
$388.57M
Debt / Equity
0.00×
Net Margin
16.4%
Shares Outstanding
165.61M sh
Source: 10-K · filed 2026-02-25 · accession 0001193125-26-068925
show_chartPrice Chart
Loading chart...
feed ALKS - Filings & News (Page 2)
ALKS
Feb 25, 2026, 9:31 AM EST
Price at Filing:
$32.41
Real-time Price:
$45.50
Change:
+$13.09 (+40%)
Market Cap:
$7.552B
ALKS
Feb 25, 2026, 7:05 AM EST
Price at Filing:
$33.60
Real-time Price:
$45.50
Change:
+$11.90 (+35%)
Market Cap:
$7.552B
ALKS
Feb 12, 2026, 7:37 AM EST
Price at Filing:
$34.92
Real-time Price:
$45.50
Change:
+$10.58 (+30%)
Market Cap:
$7.552B
ALKS
Jan 12, 2026, 8:00 AM EST
Price at Filing:
$29.60
Real-time Price:
$45.50
Change:
+$15.90 (+54%)
Market Cap:
$7.552B
ALKS
Jan 06, 2026, 7:07 AM EST
Price at Filing:
$28.82
Real-time Price:
$45.50
Change:
+$16.68 (+58%)
Market Cap:
$7.552B